Takeda – media

HiFiBiO Receives New Funding, Inks R&D Deal with Takeda

HiFiBiO Therapeutics is aspiring to work on antibody therapies for different gastrointestinal diseases, cancers and other disorders by signing a pact with Japanese Pharma and biotech company Takeda.
- Source: FierceBiotech
- 769
- August 2, 2018
biotech Company Insight Takeda
Takeda CEO Aims to Make China Second-Largest Business in Future

Takeda CEO Christophe Weber aspires to make China its second most important market in the long run, accepting it as a major task in the future.
- Source: FiercePharma
- 901
- July 22, 2018
China Market Views Takeda
Re-Investigation on FDA Approved Anti-Gout Drug Uloric

When the FDA approved this drug, there was an additional demand from the FDA to conduct post-marketing studies and assess the drug’s safety. Recently, a non-profit consumer advocacy group sent a petition requesting that the FDA should eliminate the drug from the U.S. pharma market since the drug shows significant risk of cardiovascular diseases.
- Source: FiercePharma
- 693
- June 25, 2018
cardiovascular disease Clinical Trials gout Takeda
Takeda, Japanese pharma giant clinched to Buy Shire for $61.50 billion

On Monday Takeda Pharmaceutical confirmed to acquire Shire for £45.3 billion ($61.50 billion). The final deal will be 46 percent cash and 54 percent stock.
- Source: business standard
- 697
- May 9, 2018
Market Views merger-and-acquisition Shire Takeda
New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors

New collaboration to explore the potential clinical benefits of two novel and complementary immuno-oncology mechanisms
- Source: prnewswire
- 679
- May 8, 2018
multiple cancer TAK-659 Takeda
Takeda reaches preliminary deal to buy Shire for close to $65B

Takeda has upped its offer to buy Shire $SHPG for a mix of stock and cash worth close to $65 billion, which is good enough for the Lexington, MA-based biotech to extend the deadline on their talks to May 8 after determining they were close to finalizing a pact.
- Source: endpts
- 673
- April 25, 2018
Lexington Market Views Shire Takeda
Takeda moots Shire move but big questions remain

Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an approach for the company.
- Source: takeda
- 652
- April 3, 2018
Company Insights Shire Takeda
TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe

First allogeneic stem cell therapy to receive central marketing authorization approval in Europe. Alofisel offers a new treatment option for patients who do not respond to current available therapies and may be subject to numerous invasive surgeries1
- Source: tigenix
- 610
- March 27, 2018
Alofisel EC New Approvals perianal fistulas Takeda

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.